Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice

Journal of Experimental Medicine

Volumn 197, Issue 6, 2003, Pages 777-788

  Santiago Raber, Marie Laure ^a   Baccala, Roberto ^a   Haraldsson, Katarina M ^a   Choubey, Divaker ^b   Stewart, Timothy A ^c   Kono, Dwight H ^a   Theofilopoulos, Argyrios N ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^c GENENTECH INC   (United States)

Author keywords

Autoimmunity; B 1 cells; Dendritic cells; Hemolytic anemia; Ifi202

Indexed keywords

ALPHA INTERFERON RECEPTOR; BETA INTERFERON; INTERFERON RECEPTOR; PHOSPHOPROTEIN;

ANIMAL CELL; ANIMAL DISEASE; ANIMAL TISSUE; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ARTICLE; CELL MATURATION; CELL SUBPOPULATION; CONGENIC STRAIN; CONTROLLED STUDY; DENDRITIC CELL; DNA BINDING; ERYTHROBLASTOSIS; FEMALE; GENE DELETION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETIC VARIABILITY; HEMOLYTIC ANEMIA; HOMOZYGOSITY; IMMUNE DEFICIENCY; INTERFERON PRODUCTION; KIDNEY DISEASE; LFI202 GENE; LUPUS ERYTHEMATOSUS; MORTALITY; MOUSE; NBA2 GENE; NONHUMAN; PATHOGENESIS; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN DEFICIENCY; RECEPTOR BINDING; SIGNAL TRANSDUCTION; SPLENOMEGALY; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIBODY-PRODUCING CELLS; DENDRITIC CELLS; DNA; FEMALE; HUMANS; IMMUNOGLOBULINS; INTERFERON-ALPHA; INTERFERON-BETA; KIDNEY; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE SUBSETS; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; MICE, INBRED NZB; MICE, KNOCKOUT; RECEPTOR, INTERFERON ALPHA-BETA; RECEPTORS, INTERFERON; SPLEEN; SURVIVAL RATE;

EID: 0037451124     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.20021996     Document Type: Article

References (71)

1. Biron, C.A. 2001. Interferons alpha and beta as immune regulators - a new look. Immunity. 14:661-664.
2. Taniguchi, T., and A. Takaoka. 2001. A weak signal for strong responses: interferon-alpha/beta revisited. Nat. Rev. Mol. Cell Biol. 2:378-386.
3. Theofilopoulos, A.N., S. Koundouris, D.H. Kono, and B.R. Lawson. 2001. The role of IFN-gamma in systemic lupus erythematosus: a challenge to the Th1/Th2 paradigm in autoimmunity. Arthritis Res. 3:136-141.
4. Peng, S.L., J. Moslehi, and J. Craft. 1997. Roles of interferon-gamma and interleukin-4 in murine lupus. J. Clin. Invest. 99:1936-1946.
5. Balomenos, D., R. Rumold, and A.N. Theofilopoulos. 1998. Interferon-gamma is required for lupus-like disease and lymphoaccumulation in MRL-lpr niice. J. Clin. Invest. 101:364-371.
6. Haas, C., B. Ryffel, and M. Le Hir. 1998. IFN-gamma receptor deletion prevents autoantibody production and glomerulonephritis in lupus-prone (NZB × NZW)F1 mice. J. Immunol. 160: 3713-3718.
7. Schwarting, A., T. Wada, K. Kinoshita, G. Tesch, and V.R. Kelley. 1998. IFN-gamma receptor signaling is essential for the initiation, acceleration, and destruction of autoimmune kidney disease in MRL-Fas(lpr) mice. J. Immunol. 161:494-503.
8. Ozmen, L., D. Roman, M. Fountoulakis, G. Schmid, B. Ryffel, and G. Garotta. 1995. Experimental therapy of systemic lupus erythematosus: the treatment of NZB/W mice with mouse soluble interferon-gamma receptor inhibits the onset of glomerulonephritis. Eur. J. Immunol. 25:6-12.
9. Lawson, B.R., G.J. Prud'homme, Y. Chang, H.A. Gardner, J. Kuan, D.H. Kono, and A.N. Theofilopoulos. 2000. Treatment of murine lupus with cDNA encoding IFN-gammaR/Fc. J. Clin. Invest. 106:207-215.
10. Preble, O.T., R.J. Black, R.M. Friedman, J.H. Klippel, and J. Vilcek. 1982. Systemic lupus erythematosus: presence in human serum of an unusual acid-labile leukocyte interferon. Science. 216:429-431.
11. Ioannou, Y., and D.A. Isenberg. 2000. Current evidence for the induction of autoimmune rheumatic manifestations by cytokine therapy. Arthritis Rheum. 43:1431-1442.
12. Ronnblom, L., and G.V. Alm. 2001. An etiopathogenic role for the type I IFN system in SLE. Trends Immunol. 22:427-431.
13. Blanco, P., A.K. Palucka, M. Gill, V. Pascual, and J. Banchereau. 2001. Induction of dendritic cell differentiation by IFN-alpha in systemic lupus erythematosus. Science. 294: 1540-1543.
14. Carpenter, D.F., A.D. Steinberg, P.H. Schur, and N. Talal. 1970. The pathogenesis of autoimmunity in New Zealand mice. II. Acceleration of glomerulonephritis by polyinosinic-polycytidylic acid. Lab. Invest. 23:628-634.
15. Gresser, J., L. Morel-Maroger, P. Verroust, Y. Riviere, and J.C. Guillon. 1978. Anti-interferon globulin inhibits the development of glomerulonephritis in mice infected at birth with lymphocytic choriomeningitis virus. Proc. Natl. Acad. Sci. USA. 75:3413-3416.
16. Kono, D.H., and A.N. Theofilopoulos. 2000. Genetics of systemic autoimmunity in mouse models of lupus. Int. Rev. Immunol. 19:367-387.
17. Muller, U., U. Steinhoff, L.F. Reis, S. Hemmi, J. Pavlovic, R.M. Zinkernagel, and M. Aguet. 1994. Functional role of type I and type II interferons in antiviral defense. Science. 264: 1918-1921.
18. Burlingame, R.W., R.L. Rubin, R.S. Balderas, and A.N. Theofilopoulos. 1993. Genesis and evolution of antichromatin autoantibodies in murine lupus implicates T-dependent immunization with self antigen. J. Clin. Invest. 91:1687-1696.
19. Sedgwick, J.D., and P.G. Holt. 1983. A solid-phase immunoenzymatic technique for the enumeration of specific antibody-secreting cells. J. Immunol. Methods. 57:301-309.
20. Andrews, B.S., R.A. Eisenberg, A.N. Theofilopoulos, S. Izui, C.B. Wilson, P.J. McConahey, E.D. Murphy, J.B. Roths, and F.J. Dixon. 1978. Spontaneous murine lupus-like syndromes. Clinical and immunopathological manifestations in several strains. J. Exp. Med. 148:1198-1215.
21. Ernst, B., D.S. Lee, J.M. Chang, J. Sprent, and C.D. Surh. 1999. The peptide ligands mediating positive selection in the thymus control T cell survival and homeostatic proliferation in the periphery. Immunity. 11:173-181.
22. Kozono, Y., B.L. Kotzin, and V.M. Holers. 1996. Resting B cells from New Zealand black mice demonstrate a defect in apoptosis induction following surface IgM ligation. J. Immunol. 156:4498-4503.
23. Gallucci, S., M. Lolkema, and P. Matzinger. 1999. Natural adjuvants: endogenous activators of dendritic cells. Nat. Med. 5:1249-1255.
24. Sabzevari, H., S. Propp, D.H. Kono, and A.N. Theofilopoulos. 1997. G1 arrest and high expression of cyclin kinase and apoptosis inhibitors in accumulated activated/memory phenotype CD4+ cells of older lupus mice. Eur. J. Immunol. 27: 1901-1910.
25. Rozzo, S.J., J.D. Allard, D. Choubey, T.J. Vyse, S. Izui, G. Peltz, and B.L. Kotzin. 2001. Evidence for an interferon-inducible gene, Ifi202, in the susceptibility to systemic lupus. Immunity. 15:435-443.
26. Asselin-Paturel, C., A. Boonstra, M. Dalod, I. Durand, N. Yessaad, C. Dezutter-Dambuyant, A. Vicari, A. O'Garra, C. Biron, F. Briere, and G. Trinchieri. 2001. Mouse type I IFN-producing cells are immature APCs with plasmacytoid morphology. Nat. Immunol. 2:1144-1150.
27. Nakano, H., M. Yanagita, and M.D. Gunn. 2001. Cdllc(+)b220(+)gr-l(+) cells in mouse lymph nodes and spleen display characteristics of plasmacytoid dendritic cells. J. Exp. Med. 194:1171-1178.
28. Agenes, F., and A.A. Freitas. 1999. Transfer of small resting B cells into immunodeficient hosts results in the selection of a self-renewing activated B cell population. J. Exp. Med. 189: 319-329.
29. Klinman, D.M., and A.D. Steinberg. 1987. Novel ELISA and ELISA-spot assays used to quantitate B cells and serum antibodies specific for T cell and bromelated mouse red blood cell autoantigens. J. Immunol. Methods. 102:157-164.
30. Wither, J.E., A.D. Paterson, and B. Vukusic. 2000. Genetic dissection of B cell traits in New Zealand black mice. The expanded population of B cells expressing up-regulated costimulatory molecules shows linkage to Nba2. Eur. J. Immunol. 30:356-365.
31. Murakami, M., T. Tsubata, M. Okamoto, A. Shimizu, S. Kumagai, H. Imura, and T. Honjo. 1992. Antigen-induced apoptotic death of Ly-1 B cells responsible for autoimmune disease in transgenic mice. Nature. 357:77-80.
32. Murakami, M., H. Yoshioka, T. Shirai, T. Tsubata, and T. Honjo. 1995. Prevention of autoimmune symptoms in autoimmune-prone mice by elimination of B-1 cells. Int. Immunol. 7:877-882.
33. Jameson, S.C. 2002. Maintaining the norm: T-cell homeostasis. Nat. Rev. Immunol. 2:547-556.
34. Su, L., and M. David. 1999. Inhibition of B cell receptor-mediated apoptosis by IFN. J. Immunol. 162:6317-6321.
35. Yang, C.H., A. Murti, S.R. Pfeffer, L. Basu, J.G. Kim, and L.M. Pfeffer. 2000. IFNalpha/beta promotes cell survival by activating NF-kappa B. Proc. Natl. Acad. Sci. USA. 97: 13631-13636.
36. Braun, D., I. Caramalho, and J. Demengeot. 2002. IFN-alpha/beta enhances BCR-dependent B cell responses. Int. Immunol. 14:411-419.
37. Johnson, D.G., and C.L. Walker. 1999. Cyclins and cell cycle checkpoints. Annu. Rev. Pharmacol. Toxicol. 39:295-312.
38. Gribaudo, G., L. Riera, L. Hertel, and S. Landolfo. 1999. In vitro and in vivo expression analysis of the interferon-inducible 203 gene. J. Interferon Cytokine Res. 19:129-136.
39. Choubey, D., and B.L. Kotzin. 2002. Interferon-inducible p202 in the susceptibility to systemic lupus. Front. Biosci. 7:e252-e262.
40. Theofilopoulos, A.N., and F.J. Dixon. 1985. Murine models of systemic lupus erithematosus. Adv. Immunol. 37:269-390.
41. Nisitani, S., T. Tsubata, M. Murakami, and T. Honjo. 1995. Administration of interleukin-5 or -10 activates peritoneal B-1 cells and induces autoimmune hemolytic anemia in antierythrocyte autoantibody-transgenic mice. Eur. J. Immunol. 25:3047-3052.
42. Watanabe, N., K. Ikuta, S. Nisitani, T. Chiba, and T. Honjo. 2002. Activation and differentiation of autoreactive B-1 cells by interleukin 10 induce autoimmune hemolytic anemia in Fas-deficient antierythrocyte immunoglobulin transgenic mice. J. Exp. Med. 196:141-146.
43. Velupillai, P., J. Sypek, and D.A. Ham. 1996. Interleukin-12 and -10 and gamma interferon regulate polyclonal and ligand-specific expansion of murine B-1 cells. Infect. Immun 64:4557-4560.
44. Ansel, K.M., R.B. Harris, and J.G. Cyster. 2002. CXCL13 is required for B1 cell homing, natural antibody production, and body cavity immunity. Immunity. 16:67-76.
45. Balabanian, K., A. Foussat, L. Bouchet-Delbos, J. Couderc, R. Krzysiek, A. Amara, F. Baleux, A. Portier, P. Galanaud, and D. Emilie. 2002. Interleukin-10 modulates the sensitivity of peritoneal B lymphocytes to chemokines with opposite effects on stromal cell-derived factor-1 and B-lymphocyte chemoattractant. Blood. 99:427-436.
46. Wiesemann, E., D. Sonmez, F. Heidenreich, and A. Windhagen. 2002. Interferon-beta increases the stimulatory capacity of monocyte-derived dendritic cells to induce IL-13, IL-5 and IL-10 in autologous T-cells. J. Neuroimmunol. 123: 160-169.
47. Byrnes, A.A., J.C. McArthur, and C.L. Karp. 2002. Interferon-beta therapy for multiple sclerosis induces reciprocal changes in interleukin-12 and interleukin-10 production. Ann. Neurol. 51:165-174.
48. Le Bon, A., G. Schiavoni, G. D'Agostino, I. Gresser, F. Belardelli, and D.F. Tough. 2001. Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity. 14:461-470.
49. Lin, Q., C. Dong, and M.D. Cooper. 1998. Impairment of T and B cell development by treatment with a type I interferon. J. Exp. Med. 187:79-87.
50. Chen, S.Y., Y. Takeoka, L. Pike-Nobile, A.A. Ansari, R. Boyd, and M.E. Gershwin. 1997. Autoantibody production and cytokine profiles of MHC class I (beta2-microglobulin) gene deleted New Zealand black (NZB) mice. Clin. Immunol. Immunopathol. 84:318-327.
51. Penninger, J.M., C. Sirard, H.W. Mittrücker, A. Chidgey, I. Kozieradzki, M. Nghiem, A. Hakem, T. Kimura, E. Timms, R. Boyd, et al. 1997. The interferon regulatory transcription factor IRF-1 controls positive and negative selection of CD8+ thymocytes. Immunity. 7:243-254.
52. Matsuyama, T., T. Kimura, M. Kitagawa, K. Pfeffer, T. Kawakami, N. Watanabe, T.M. Kundig, R. Amakawa, K. Kishihara, and A. Wakeham. 1993. Targeted disruption of IRF-1 or IRF-2 results in abnormal type I IFN gene induction and aberrant lymphocyte development. Cell. 75:83-97.
53. Tada, Y., A. Ho, T. Matsuyama, and T.W. Mak. 1997. Reduced incidence and severity of antigen-induced autoimmune diseases in mice lacking interferon regulatory factor-1. J. Exp. Med. 185:231-238.
54. Nakazawa, T., J. Satoh, K. Takahashi, Y. Sakata, F. Ikehata, Y. Takizawa, S.I. Bando, T. Housai, Y. Li, C. Chen, et al. 2001. Complete suppression of insulitis and diabetes in NOD mice lacking interferon regulatory factor-1. J. Autoimmun. 17:119-125.
55. Hida, S., K. Ogasawara, K. Sato, M. Abe, H. Takayanagi, T. Yokochi, T. Sato, S. Hirose, T. Shirai, S. Taki, and T. Taniguchi. 2000. CD8(+) T cell-mediated skin disease in mice lacking IRF-2, the transcriptional attenuator of interferon-alpha/beta signaling. Immunity. 13:643-655.
56. Marrack, P., J. Kappler, and T. Mitchell. 1999. Type I interferons keep activated T cells alive. J. Exp. Med. 189:521-529.
57. Tough, D.F., P. Borrow, and J. Sprent. 1996. Induction of bystander T cell proliferation by viruses and type I interferon in vivo. Science. 272:1947-1950.
58. Zhang, X.H., S.Q. Sun, I.K. Hwang, D.F. Tough, and J. Sprent. 1998. Potent and selective stimulation of memory-phenotype CD8+ T cells in vivo by IL-15. Immunity. 8:591-599.
59. Ogasawara, K., S. Hida, Y. Weng, A. Saiura, K. Sato, H. Takayanagi, S. Sakaguchi, T. Yokochi, T. Kodama, M. Naitoh, et al. 2002. Requirement of the IFN-α/Β-induced CXCR3 chemokine signalling for CD8(+) T cell activation. Genes Cells. 7:309-320.
60. Taniguchi, T., K. Ogasawara, A. Takaoka, and N. Tanaka. 2001. IRF family of transcription factors as regulators of host defense. Annu. Rev. Immunol. 19:623-655.
61. Vyse, T.J., and B.L. Kotzin. 1998. Genetic susceptibility to systemic lupus erythematosus. Annu. Rev. Immunol. 16:261-292.
62. Wakeland, E.K., K. Liu, R.R. Graham, and T.W. Behrens. 2001. Delineating the genetic basis of systemic lupus erythematosus. Immunity. 15:397-408.
63. Takaoka, A., Y. Mitani, H. Suemori, M. Sato, T. Yokochi, S. Noguchi, N. Tanaka, and T. Taniguchi. 2000. Cross talk between interferon-gamma and -alpha/beta signaling components in caveolar membrane domains. Science. 288:2357-2360.
64. Balasa, B., C. Deng, J. Lee, L.M. Bradley, D.K. Dalton, P. Christadoss, and N. Sarvetnick. 1997. Interferon gamma (IFN-gamma) is necessary for the genesis of acetylcholine receptor-induced clinical experimental autoimmune myasthenia gravis in mice. J. Exp. Med. 186:385-391.
65. Zhang, G.X., B.G. Xiao, X.F. Bai, P.H. van der Meide, A. Orn, and H. Link. 1999. Mice with IFN-gamma receptor deficiency are less susceptible to experimental autoimmune myasthenia gravis. J. Immunol. 162:3775-3781.
66. Chu, C.Q., S. Wittmer, and D.K. Dalton. 2000. Failure to suppress the expansion of the activated CD4 T cell population in interferon gamma-deficient mice leads to exacerbation of experimental autoimmune encephalomyelitis. J. Exp. Med. 192:123-128.
67. Jahng, A.W., I. Maricic, B. Pedersen, N. Burdin, O. Naidenko, M. Kronenberg, Y. Koezuka, and V. Kumar. 2001. Activation of natural killer T cells potentiates or prevents experimental autoimmune encephalomyelitis. J. Exp. Med. 194: 1789-1799.
68. Stewart, T.A., B. Hultgren, X. Huang, S. Pitts-Meek, J. Hully, and N.J. MacLachlan. 1993. Induction of type I diabetes by interferon-alpha in transgenic mice. Science. 260: 1942-1946.
69. Deng, C., E. Goluszko, S. Baron, B. Wu, and P. Christadoss. 1996. IFN-alpha therapy is effective in suppressing the clinical experimental myasthenia gravis. J. Immunol. 157:5675-5682.
70. Shenoy, M., S. Baron, B. Wu, E. Goluszko, and P. Christadoss. 1995. IFN-alpha treatment suppresses the development of experimental autoimmune myasthenia gravis. J. Immunol. 154:6203-6208.
71. Martin, R., C.S. Sturzebecher, and H.F. McFarland. 2001. Immunotherapy of multiple sclerosis: where are we? Where should we go? Nat. Immunol. 2:785-788.